SCHEMBL1924749

SCHEMBL1924749

O=C(CC(=O)C(F)(F)F)c1ccncc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLOD2 O00469 5/20 1.00
PLOD3 O60568 3/20 1.00
PLOD1 Q02809 3/20 1.00
ALDH1A1 P00352 3/20 0.58
CYP1A2 P05177 2/20 0.58
CYP3A4 P08684 2/20 0.58
CYP2D6 P10635 2/20 0.58
CYP2C19 P33261 2/20 0.58
CYP2C9 P11712 1/20 0.58
HPGD P15428 1/20 0.58
HIF1A Q16665 1/20 0.58
KDM4E B2RXH2 3/20 0.47
MPO P05164 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
CYP2A6 P11509 1/20 0.47
NAPRT Q6XQN6 1/20 0.43
PTPN1 P18031 1/20 0.43
GAA P10253 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5805684 0.98 PLOD2 (0.96) PLOD2PLOD3PLOD1ALDH1A1CYP1A2
SCHEMBL10948430 0.81 PLOD2 (0.83) PLOD2PLOD3PLOD1ALDH1A1CYP1A2
SCHEMBL313164 0.81 PLOD2 (0.70) PLOD2PLOD3PLOD1ALDH1A1PTPN1
SCHEMBL21408730 0.80 PLOD2 (0.67) PLOD2PLOD3PLOD1ALDH1A1CYP1A2
SCHEMBL523476 0.80 PLOD2 (0.69) PLOD2PLOD3PLOD1ALDH1A1CYP1A2
SCHEMBL1925385 0.79 PLOD2 (1.00) PLOD2PLOD3PLOD1ALDH1A1HIF1A
SCHEMBL711849 0.78 PLOD2 (1.00) PLOD2PLOD3PLOD1HPGDKDM4E
SCHEMBL9654173 0.78 PLOD2 (0.67) PLOD2PLOD3PLOD1ALDH1A1CYP1A2
SCHEMBL10613054 0.78 PLOD2 (0.67) PLOD2PLOD3PLOD1ALDH1A1CYP1A2
SCHEMBL9630807 0.78 PLOD2 (0.67) PLOD2PLOD3PLOD1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119161869-B Rare earth europium metal complex stress luminescent material and preparation method and application thereof 宁夏大学 2025-06-24 CN claimed
CN-119161869-A Rare earth europium metal complex stress luminescent material and preparation method and application thereof 宁夏大学 2024-12-20 CN claimed
CN-121108160-A Down-conversion luminescent material based on pyridyl beta-diketone rare earth complex, and preparation method and application thereof 宁夏医科大学 2025-12-12 CN disclosed
CN-119161869-B Rare earth europium metal complex stress luminescent material and preparation method and application thereof 宁夏大学 2025-06-24 CN disclosed
CN-119161869-B Rare earth europium metal complex stress luminescent material and preparation method and application thereof 宁夏大学 2025-06-24 CN disclosed
WO-2025049419-A1 PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS GENZYME CORPORATION (US) 2025-03-06 WO disclosed
CN-119161869-A Rare earth europium metal complex stress luminescent material and preparation method and application thereof 宁夏大学 2024-12-20 CN disclosed
CN-119161869-A Rare earth europium metal complex stress luminescent material and preparation method and application thereof 宁夏大学 2024-12-20 CN disclosed
WO-2024215863-A2 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2024-10-17 WO disclosed
EP-1670801-B1 PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-06-08 EP disclosed
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20050130992-A1 Pyrazolo-pyridine F. HOFFMANN-LA ROCHE AG (CH) 2005-06-16 US disclosed
WO-2005040171-A1 PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-05-06 WO disclosed
EP-1495005-A1 PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS Pfizer Japan Inc. (JP) 2005-01-12 EP disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents HIRANO MISATO (JP) 2004-01-29 US disclosed
WO-2003087061-A1 PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER JAPAN INC. (JP) 2003-10-23 WO disclosed
US-4582833-A HYPOTENSIVE AGENTS AMERICAN CYANAMID COMPANY (US) 1986-04-15 US disclosed
US-4576943-A NERVOUS SYSTEM DISORDERS, SEDATIVES, HYPOTENSIVE AGENTS AMERICAN CYANAMID COMPANY (US) 1986-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents PTGER1, PTGS1, PTGIR PLOD2 3220/4885PLOD3 3597/4885PLOD1 2898/4885
US-20050130992-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR PLOD2 3738/4885PLOD3 3474/4885PLOD1 3848/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 PLOD2 4023/4885PLOD3 2487/4885PLOD1 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.